
-
IDEAYA Biosciences NASDAQ:IDYA IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.
Location: 7000 Shoreline Ct Ste 350, California, 94080-7604, US | Website: www.ideayabio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.067B
Cash
676.3M
Avg Qtr Burn
-61.9M
Short % of Float
12.32%
Insider Ownership
1.04%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Darovasertib Details Uveal melanoma | Phase 3 Initiation | |
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer | Phase 2/3 Data readout | |
Darovasertib Details Cancer, Ocular melanoma | Phase 2 Data readout | |
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma | Phase 2 Data readout | |
IDE397 (MAT2A) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer | Phase 1/2 Data readout | |
GSK101 (IDE705) + niraparib Details Cancer, Solid tumor/s | Phase 1/2 Update | |
IDE849 (SHR-4849) Details Cancer, Small cell lung cancer | Phase 1 Data readout | |
IDE397 (MAT2A) + Trodelvy Details MTAP-Deletion Urothelial Cancer | Phase 1 Data readout | |
IDE161 +/- KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer | Phase 1 Update | |
IDE275 (GSK959) Details Solid tumor/s, Cancer | Phase 1 Initiation | |
IDE397 (MAT2A) +/- AMG 193 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Failed Discontinued |